erlotinib hydrochloride has been researched along with Pleural Effusion, Malignant in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, M; Gemma, A; Hagiwara, K; Hino, M; Kobayashi, K; Kubota, K; Miyanaga, A; Nishitsuji, M; Noro, R; Seike, M; Shimokawa, T; Usuki, J; Yomota, M | 1 |
| Boisdron-Celle, M; Fey, L; Hureaux, J; Morel, A; Rieux, C; Urban, T | 1 |
| Leighl, NB; Zer, A | 1 |
| Aurisicchio, L; Bergantino, F; Cherubini, E; Ciliberto, G; Costantini, S; De Vitis, C; Fenizia, F; Ferrara, FF; Giarnieri, E; Giovagnoli, MR; Lambiase, M; Mancini, R; Mariotta, S; Normanno, N; Noto, A; Ricci, A; Roscilli, G; Torrisi, MR | 1 |
| Billheimer, D; Brahmer, J; Carbone, D; Chen, H; Chen, S; Dang, TP; Herbst, R; Lee, JW; Massion, P; Salmon, S; Sandler, A; Schiller, J; Shyr, Y; Tran, H; Tsao, A | 1 |
| Ishida, T; Katsuura, Y; Minemura, H; Misa, K; Munakata, M; Tachihara, M; Uematsu, M | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK | 1 |
| Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Guo, H; Kang, Y; Li, Y; Lin, D; Liu, Q; Tian, G; Wan, Y; Yao, Z | 1 |
| Baik, CS; Chow, LQ; Eaton, KD; Pritchard, CC | 1 |
1 review(s) available for erlotinib hydrochloride and Pleural Effusion, Malignant
| Article | Year |
|---|---|
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
2 trial(s) available for erlotinib hydrochloride and Pleural Effusion, Malignant
| Article | Year |
|---|---|
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Pleural Effusion, Malignant; Pleurodesis; Prognosis; Survival Rate | 2020 |
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Prognosis; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2009 |
8 other study(ies) available for erlotinib hydrochloride and Pleural Effusion, Malignant
| Article | Year |
|---|---|
[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biological Assay; Cell Proliferation; DNA Mutational Analysis; Erlotinib Hydrochloride; Exome; Female; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Metabolic Networks and Pathways; Models, Biological; Mutation; Pleural Effusion, Malignant; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Ascites; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Prednisolone; Quinazolines | 2011 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth | 2011 |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic | 2012 |
EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoembryonic Antigen; Drainage; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tissue Polypeptide Antigen; Treatment Outcome | 2012 |
EGFR mutations in squamous cell lung cancer in never-smokers.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Epidural Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Smoking; Thoracic Vertebrae | 2013 |